| Dr Katherine R Long, MD | |
|
3680 Nw Samaritan Dr, Corvallis, OR 97330-3737 | |
| (541) 754-1150 | |
| (541) 753-1789 |
| Full Name | Dr Katherine R Long |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 3680 Nw Samaritan Dr, Corvallis, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932181013 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD25210 (Oregon) | Primary |
| Entity Name | Corvallis Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649227265 PECOS PAC ID: 1456244540 Enrollment ID: O20040203000916 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).
Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of August 25, 2011 for the review of the New Drug Application (NDA) for FIRAZYR(R) (icatibant) for the treatment of acute attacks (Types I and II) of hereditary angioedema (HAE). This 6 month review timeline is consistent with review as a Class II resubmission.
The Food and Drug Administration's approval of a new vaccine that targets five additional strains of human papilloma virus (HPV) fortifies a proven cancer-prevention weapon, according to Ronald A. DePinho, M.D., president of The University of Texas MD Anderson Cancer Center.
The Associated Press: "A federal judge on Tuesday refused to lift his order blocking federal funding for some stem cell research, saying that a 'parade of horribles' predicted by federal officials would not happen. Medical researchers value stem cells because they are master cells that can turn into any tissue of the body.
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the appointment of Mark Capone, former President and CEO of Myriad Genetics to its Board as an independent non-executive director.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Katherine R Long, MD 444 Nw Elks Dr, Corvallis, OR 97330-3745 Ph: (541) 754-1150 | Dr Katherine R Long, MD 3680 Nw Samaritan Dr, Corvallis, OR 97330-3737 Ph: (541) 754-1150 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).
Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of August 25, 2011 for the review of the New Drug Application (NDA) for FIRAZYR(R) (icatibant) for the treatment of acute attacks (Types I and II) of hereditary angioedema (HAE). This 6 month review timeline is consistent with review as a Class II resubmission.
The Food and Drug Administration's approval of a new vaccine that targets five additional strains of human papilloma virus (HPV) fortifies a proven cancer-prevention weapon, according to Ronald A. DePinho, M.D., president of The University of Texas MD Anderson Cancer Center.
The Associated Press: "A federal judge on Tuesday refused to lift his order blocking federal funding for some stem cell research, saying that a 'parade of horribles' predicted by federal officials would not happen. Medical researchers value stem cells because they are master cells that can turn into any tissue of the body.
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the appointment of Mark Capone, former President and CEO of Myriad Genetics to its Board as an independent non-executive director.
› Verified 5 days ago
Dr. Destiny Jennifer Gmelch, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 3600 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-768-5111 | |
Chinh T. Le, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 530 Nw 27th St, Corvallis, OR 97330 Phone: 541-766-6835 | |
Elizabeth Ranae Davis, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 3680 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-754-1150 | |
Wayne Joseph Merback, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 3600 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-768-5111 | |
Dr. Lon Mcquillan, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 777 Nw 9th St, Suite 320, Corvallis, OR 97330 Phone: 541-768-4900 | |
Ms. Kathryn I Mcquillan, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 3680 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-754-1150 | |
Jill A Miller, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 3680 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-754-1150 |